

許麗卿 副教授

• 研究領域：

生物藥學、分子藥理學、癌症生物學、分子及細胞生物學

— 研究方向：

1. 篩選新穎葡萄糖轉運蛋白抑制劑作為降血糖或抗癌新藥與其作用機制之研究
2. 抗癌藥物合併使用新策略之開發
3. 探索分子標的以開發抗癌新藥
4. 腫瘤抑制蛋白之分子與功能研究

— 代表著作：

1. Ting-Yu Kao, Hwa-Wei Wu, Shoei-Sheng Lee, Pi-Hui Liang, Jih-Hwa Guh, Lih-Ching Hsu (2021). Characterization of a fluorescent glucose derivative 1-NBDG and its application in the identification of natural SGLT1/2 inhibitors. *Journal of Food and Drug Analysis*, 29 (3), 521-532.
2. Tzu-En Huang, Yi-Ning Deng, Jui-Ling Hsu, Wohn-Jenn Leu, Elena Marchesi, Massimo L. Capobianco, Paolo Marchetti, Maria Luisa Navacchia, Jih-Hwa Guh, Daniela Perrone, Lih-Ching Hsu (2020). Evaluation of the anticancer activity of a bile acid-dihydroartemisinin hybrid ursodeoxycholic dihydroartemisinin in hepatocellular carcinoma cells. *Frontiers in Pharmacology*, 11, 599067.
3. Yu-Liang Li, Hao-Cheng Weng, Jui-Ling Hsu, Shu-Wha Lin, Jih-Hwa Guh, Lih-Ching Hsu (2019). The combination of MK-2206 and WZB117 exerts a synergistic cytotoxic effect against breast cancer cells. *Frontiers in Pharmacology*, 10, 1311.
4. Elena Marchesi, Nicola Chinaglia, Massimo L. Capobianco, Paolo Marchetti, Tzu-En Huang, Hao-Cheng Weng, Jih-Hwa Guh, Lih-Ching Hsu, Daniela Perrone, Maria Luisa Navacchia (2019). Dihydroartemisinin-bile acid hybridization as an effective approach to enhance dihydroartemisinin anticancer activity. *ChemMedChem*, 14, 779-787.
5. Wei-Ting Lai, Kai-Lin Cheng, Riccardo Baruchello, Riccardo Rondanin, Paolo Marchetti, Daniele Simoni, Ray M. Lee, Jih-Hwa Guh, Lih-Ching Hsu (2016). Hemiasterlin derivative (R)(S)(S)-BF65 and Akt inhibitor MK-2206 synergistically inhibit SKOV3 ovarian cancer cell growth. *Biochemical Pharmacology*, 113, 12-23.

